🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Myeloma community, we're getting together on 4/26 in #Edina —join us! At this free IMF RCW, you'll be able to have Q&A with leading myeloma experts, network with other myeloma patients, gain insights on the latest treatments, and more. Register now: mmsm.link/40HkkuC

International candidates will be considered as long as they have USMLEs and can be like licensed in the US Mayo Amyloid

Excellent analysis of localized AL amyloid led by my colleague Danai Dima and her Cleveland Clinic fellowship mentors! Localized AL amyloid can recur in lungs & GI, but - out of 146 cases - not a single progression to systemic AL amyloidosis. Disease biology different! #MMsm

End of an era at Mayo Clinic Hematology-Oncology Fellowship fellowship! Thanks for vouching for us all along Dr. Hobday! We were fortunate to have trained under your aegis! Super excited for the amazing team of Jonas Paludo Urshila Durani Brittany Siontis to lead the program to new heights!

Rahul Banerjee, MD, FACP Danai Dima Cleveland Clinic Beth Faiman PhD Jack Khouri Louis Williams Most of these patients don’t even need a marrow to exclude systemic AL if FLCs/IFE are normal. Good to see overall patterns agree with our 2017 paper. pubmed.ncbi.nlm.nih.gov/28483059/

Carfilzomib for myeloma: I don’t recommend any more than 56 mg/m2 once a week Our study results show that higher doses do not offer more benefit. Sharlene Dong Rahul Banerjee, MD, FACP Gurbakhash Kaur Aimaz Afrough Murali Janakiram Blood Cancer Journal nature.com/articles/s4140…

Yale Myeloma group is recruiting a junior faculty myeloma specialist at the Assistant Professor level. Yale Myeloma team is a wonderfully collaborative group with great research and a lot of potential for growth. Interested individuals please email [email protected]

Solitary plasmacytoma: single-institution experience, + systematic review & meta-analysis. Patients with >/=10% PC in BM, dFLC >50 mg/L and bone (vs. extramedullary) plasmacytoma did worse #mmsm #bmtsm Shaji Kumar ashpublications.org/bloodadvances/…

2012 a friend said- “Science Fiction” 2015 we dared to dream Sharing 🇮🇳 1st novel #CARTCellRx Ph 1/1b trial We report 92% ORR 3 dose levels nature Blood Cancer Journal Rahul Purwar ImmunoACT CAR-T & Cell Therapy Centre (CTCTC) ACTREC_TMC Nirali Shah Tata Memorial Hospital Swaminathan K Alka Dwivedi rdcu.be/ei7xh

The ⁦International Myeloma Foundation⁩ Regional Community Workshop is in Edina, MN today! ⁦Joselle Cook⁩ is helping patients & care partners to understand the basics of #myeloma. #mmsm ⁦Teresa Miceli. ❤️&☮️4🌎⁩ ⁦Sylviads⁩ ⁦Jenn Wieworka⁩ ⁦Michael Tuohy⁩

Management of #myeloma side effects leads to better Quality of Life! Thank you to ⁦Teresa Miceli. ❤️&☮️4🌎⁩ of the ⁦International Myeloma Foundation⁩ Nurse Leadership Board presenting in Edina, MN #mmsm

We call for a paradigm shift in development of immunotherapy drugs, especially bispecifics. Leukemia Journal These drugs have therapeutic effects that last a long time. We need to reduce frequency and switch to limited duration treatment to avoid toxicity. nature.com/articles/s4137…

Cilta-cel associated Parkinsonism remains a challenge. Instead of going right to high dose Cy which can be toxic to circulating CAR T cells, we opted to try intrathecal chemotherapy in 5 consecutive cases. 4/5 pts had a response and 3 complete resolution! IT chemo seemed to be

The CT Multiple #Myeloma Fighters Information Group virtually meets May 13 from 6-8 pm eastern. Special Guest Speaker, Sergio Jablon will share his journey & humor. Group website: ct.support.myeloma.org #mmsm International Myeloma Foundation Contact us for details and meeting link.Michael Tuohy

I see how many trials struggle to accrue, close and readout. I also see how many succeed and change treatment paradigm. The challenges and triumphs of being a PI is real. They have to be resilient, visionary and have a crystall ball of how other trials and the landscape 3-5

The ECOG MM committee ECOG-ACRIN Cancer Research Group has started ,chaired by Vincent Rajkumar - Several new trials coming through

Our new paper out now in Blood Reviews, on a potentially groundbreaking therapy for AL Amyloidosis, CAEL-101 sciencedirect.com/science/articl…

An important early morning symposium at the ⁦COMy⁩ 2025. ⁦Claudio Cerchione⁩ ⁦marivi mateos⁩ ⁦IACH⁩

The multiple myelomas -- current concepts in cytogenetic classification and therapy [Apr 23, 2018] Shaji Kumar & Vincent Rajkumar NatureRevClinOncol ow.ly/8ki130mCyA8 #mmsm #camoldx

This is amazing! So much of science is brilliance of the people involved with a little sprinkle of serendipity!